Evandro de Azambuja, MD, PhD· @E_de_Azambuja · X·· 2 days agoScore90
Body
6-year results of Natalee (ribociclib): improvements in OS, BCSS, iDFS, DRFS - some subgroups analyses still required
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @Annals_Oncology
413 views · 13 likes · 6 reposts · 1 reply
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgReplies in this thread
- Cohen carine@carinecccc
@E_de_Azambuja @myESMO @Annals_Oncology We miss the OS curves in Europe, And the table of the deaths for other causes, which is driven by long term cardiovascular toxicities
Source: Evandro de Azambuja, MD, PhD · x.com